SCHEDULE: Lind Global Fund II Discloses 8.8% Stake in Tenax Therapeutics

Lind Global Fund II LP, along with its general partner and managing member, reported beneficial ownership of 8.8% of Tenax Therapeutics, Inc. common stock through warrants.

Summary

• Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13G.
• The filing reports beneficial ownership of 442,480 warrants to purchase shares of common stock of TENAX THERAPEUTICS, INC.
• This represents 8.8% of the class of Common Stock, par value $0.0001 per share.
• The warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine beneficial ownership disclosure and does not contain performance or strategic updates for the issuer.

Positives

• An institutional investor, Lind Global Fund II LP, holds a significant stake in Tenax Therapeutics, indicating potential investor interest.

Negatives

• The warrants held by the reporting persons cannot be exercised if beneficial ownership would exceed 9.9%, which limits the investor's immediate ability to increase their stake beyond this threshold.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership report.

Industry Context

This filing is a routine disclosure of an institutional investor's stake in a publicly traded company, which is a common occurrence in the financial markets. It does not provide specific insights into Tenax Therapeutics' industry position or broader market trends.

Stakeholder Impact

• Shareholders may view the continued significant stake by an institutional investor as a sign of ongoing interest in the company.

Key Dates

Keywords

Tenax Therapeutics, Lind Global Fund II, Schedule 13G, Beneficial Ownership, Warrants, Common Stock, Institutional Investor